Insitro CEO Daphne Koller on ‘potentially destructive’ AI hype, Nvidia chips and biotech’s data problem

SAN JOSE, CA — For all its promise, artificial intelligence has routinely fallen into the hype trap.

Daphne Koller, a self-described “OG AI person,” hopes biotech can steer clear this time around, while not being particularly optimistic herself about the chances of tamping down excitement to healthy levels. Koller, 55, has been working in AI for about three decades, starting as a Stanford University professor in 1995 and joining Alphabet’s biotech Calico Life Sciences as its chief computing officer in 2016.

In 2018, Koller founded her own biotech, insitro, which has grown into one of AI bio’s heavyweights, raising over $643 million and commanding a $2.5 billion valuation, according to PitchBook, although the company still has yet to put its first drug candidate into the clinic.

Endpoints News caught up with Koller on the final day of Nvidia’s annual developer conference, moments after she…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks